- Published on
KembaraXtra-Medicine — Antiphospholipid Antibody Syndrome
Antiphospholipid antibody syndrome (APS) is the most common acquired thrombophilia and is defined by the occurrence of arterial or venous thrombosis and/or characteristic pregnancy morbidity in the presence of persistent antiphospholipid antibodies. These antibodies are directed against anionic phospholipids or phospholipid-binding protein cofactors and promote a hypercoagulable state by stimulating procoagulant pathways while inhibiting fibrinolysis. This process activates downstream mechanisms including mTOR upregulation, Toll-like receptor signaling, and activation of endothelial cells, monocytes, neutrophils, platelets, complement, and proinflammatory cytokines.
Three major antiphospholipid antibodies have been identified: anticardiolipin antibodies, lupus anticoagulant, and anti–β2-glycoprotein I antibodies. APS may occur as a primary disorder or secondary to rheumatologic disease, most commonly systemic lupus erythematosus. The syndrome can affect virtually all organ systems and is associated with venous and arterial thrombosis, recurrent fetal loss, and hematologic abnormalities such as thrombocytopenia and microangiopathic hemolytic anemia.
Antiphospholipid antibodies may be detected in up to 5% of healthy individuals, though only a subset develop clinical APS. These antibodies are found with increased frequency in patients with stroke, myocardial infarction, deep vein thrombosis, and pregnancy complications. APS most commonly affects young to middle-aged adults. Thrombotic risk is increased in the presence of autoimmune disease and is further amplified by acquired risk factors such as pregnancy, oral contraceptive use, smoking, malignancy, prolonged immobilization, and hyperlipidemia. Long-term prognosis is generally favorable with treatment, with high survival rates and improved pregnancy outcomes, although complications such as prematurity and fetal growth restriction remain common.
There are no pathognomonic physical findings in APS. Clinical manifestations are highly variable and reflect thrombotic involvement of multiple organ systems. Venous thrombosis is the most common presentation, particularly deep vein thrombosis of the lower extremities, though thrombosis may occur in atypical venous sites. Arterial thrombosis most frequently affects cerebral vessels, leading to stroke or transient ischemic attack, but may also involve coronary, renal, mesenteric, or peripheral arteries. Recurrent thrombosis is a hallmark feature of APS.
Other commonly involved systems include the pulmonary system, with pulmonary embolism and pulmonary hypertension; the cardiovascular system, with valvular disease, myocardial infarction, and intracardiac thrombosis; the gastrointestinal system, with ischemic abdominal pain and organ infarction; and the renal system, with hypertension, infarction, and glomerular disease. Cutaneous findings such as livedo reticularis, skin necrosis, and digital gangrene may be present. Obstetric manifestations include recurrent miscarriage, fetal death, preeclampsia, placental insufficiency, and premature delivery.
A rare but severe manifestation is catastrophic antiphospholipid syndrome, characterized by rapid development of widespread small-vessel thrombosis involving three or more organs within a short period. This condition carries a high mortality rate and requires prompt recognition and aggressive treatment.
Diagnosis of APS requires fulfillment of at least one clinical criterion and one laboratory criterion. Clinical criteria include objectively confirmed arterial, venous, or small-vessel thrombosis, or defined pregnancy morbidity. Laboratory criteria require persistent positivity of lupus anticoagulant, anticardiolipin antibodies, or anti–β2-glycoprotein I antibodies on two occasions at least 12 weeks apart. Evaluation should also exclude inherited and acquired hypercoagulable states and alternative causes of pregnancy loss.
Management of APS centers on anticoagulation. Acute thrombotic events are treated initially with unfractionated or low-molecular-weight heparin, followed by long-term vitamin K antagonist therapy such as warfarin. Standard-intensity anticoagulation is preferred for venous thrombosis, while arterial events may require combined anticoagulant and antiplatelet therapy. Direct oral anticoagulants are not recommended in high-risk APS, particularly in patients with triple-positive antibody profiles, due to increased rates of recurrent thrombosis.
In pregnancy, warfarin is contraindicated because of teratogenicity. Women with APS and pregnancy morbidity are treated with low-dose aspirin combined with unfractionated or low-molecular-weight heparin to improve pregnancy outcomes. Long-term anticoagulation is often required indefinitely because of the high risk of recurrence. Referral to hematology, rheumatology, and obstetric specialists is recommended for comprehensive management and long-term follow-up.
Antiphospholipid antibody syndrome (APS) is the most common acquired thrombophilia and is defined by the occurrence of arterial or venous thrombosis and/or characteristic pregnancy morbidity in the presence of persistent antiphospholipid antibodies. These antibodies are directed against anionic phospholipids or phospholipid-binding protein cofactors and promote a hypercoagulable state by stimulating procoagulant pathways while inhibiting fibrinolysis. This process activates downstream mechanisms including mTOR upregulation, Toll-like receptor signaling, and activation of endothelial cells, monocytes, neutrophils, platelets, complement, and proinflammatory cytokines.
Three major antiphospholipid antibodies have been identified: anticardiolipin antibodies, lupus anticoagulant, and anti–β2-glycoprotein I antibodies. APS may occur as a primary disorder or secondary to rheumatologic disease, most commonly systemic lupus erythematosus. The syndrome can affect virtually all organ systems and is associated with venous and arterial thrombosis, recurrent fetal loss, and hematologic abnormalities such as thrombocytopenia and microangiopathic hemolytic anemia.
Antiphospholipid antibodies may be detected in up to 5% of healthy individuals, though only a subset develop clinical APS. These antibodies are found with increased frequency in patients with stroke, myocardial infarction, deep vein thrombosis, and pregnancy complications. APS most commonly affects young to middle-aged adults. Thrombotic risk is increased in the presence of autoimmune disease and is further amplified by acquired risk factors such as pregnancy, oral contraceptive use, smoking, malignancy, prolonged immobilization, and hyperlipidemia. Long-term prognosis is generally favorable with treatment, with high survival rates and improved pregnancy outcomes, although complications such as prematurity and fetal growth restriction remain common.
There are no pathognomonic physical findings in APS. Clinical manifestations are highly variable and reflect thrombotic involvement of multiple organ systems. Venous thrombosis is the most common presentation, particularly deep vein thrombosis of the lower extremities, though thrombosis may occur in atypical venous sites. Arterial thrombosis most frequently affects cerebral vessels, leading to stroke or transient ischemic attack, but may also involve coronary, renal, mesenteric, or peripheral arteries. Recurrent thrombosis is a hallmark feature of APS.
Other commonly involved systems include the pulmonary system, with pulmonary embolism and pulmonary hypertension; the cardiovascular system, with valvular disease, myocardial infarction, and intracardiac thrombosis; the gastrointestinal system, with ischemic abdominal pain and organ infarction; and the renal system, with hypertension, infarction, and glomerular disease. Cutaneous findings such as livedo reticularis, skin necrosis, and digital gangrene may be present. Obstetric manifestations include recurrent miscarriage, fetal death, preeclampsia, placental insufficiency, and premature delivery.
A rare but severe manifestation is catastrophic antiphospholipid syndrome, characterized by rapid development of widespread small-vessel thrombosis involving three or more organs within a short period. This condition carries a high mortality rate and requires prompt recognition and aggressive treatment.
Diagnosis of APS requires fulfillment of at least one clinical criterion and one laboratory criterion. Clinical criteria include objectively confirmed arterial, venous, or small-vessel thrombosis, or defined pregnancy morbidity. Laboratory criteria require persistent positivity of lupus anticoagulant, anticardiolipin antibodies, or anti–β2-glycoprotein I antibodies on two occasions at least 12 weeks apart. Evaluation should also exclude inherited and acquired hypercoagulable states and alternative causes of pregnancy loss.
Management of APS centers on anticoagulation. Acute thrombotic events are treated initially with unfractionated or low-molecular-weight heparin, followed by long-term vitamin K antagonist therapy such as warfarin. Standard-intensity anticoagulation is preferred for venous thrombosis, while arterial events may require combined anticoagulant and antiplatelet therapy. Direct oral anticoagulants are not recommended in high-risk APS, particularly in patients with triple-positive antibody profiles, due to increased rates of recurrent thrombosis.
In pregnancy, warfarin is contraindicated because of teratogenicity. Women with APS and pregnancy morbidity are treated with low-dose aspirin combined with unfractionated or low-molecular-weight heparin to improve pregnancy outcomes. Long-term anticoagulation is often required indefinitely because of the high risk of recurrence. Referral to hematology, rheumatology, and obstetric specialists is recommended for comprehensive management and long-term follow-up.
0 Comments
